Advisory Panel Members Respond To Wood Editorial In NEJM On Plan B
This article was originally published in The Tan Sheet
Executive Summary
An evaluation of package information for over-the-counter levonorgestrel needs to include typical-use and not just optimal-use rates, according to a letter to the editor in the June 3 New England Journal of Medicine signed by members of FDA's Reproductive Health Drugs Advisory Committee